MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases
MBX•Obesity program and balance sheet
The obesity candidate MBX 4291 targets once-monthly dosing, with 12-week Phase 1 MAD results guided to Q4 2026.
Cash, cash equivalents, and marketable securities totaled $418.6 million as of June 30, 2026, with runway projected into 2029.
Catalyst schedule and canvuparatide data
MBX Biosciences outlined a catalyst schedule led by canvuparatide (MBX 2109) Phase 3 initiation in Q3 2026.
Canvuparatide Phase 2 Avail responder rates were shown at 79% at 12 weeks, 63% at 6 months, and 57% at 1 year.
The Phase 3 design calls for N=160, 3:1 randomization, a 26-week placebo-controlled period, and a primary composite responder endpoint at Week 26.
